BMEA (Biomea Fusion) Intangible Assets : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Biomea Fusion's intangible assets for the quarter that ended in Sep. 2024 was $0.00 Mil.

Biomea Fusion Intangible Assets Historical Data

The historical data trend for Biomea Fusion's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomea Fusion Intangible Assets Chart

Biomea Fusion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Intangible Assets

Biomea Fusion Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Intangible Assets	Get a 7-Day Free Trial															-	-	-	-	-

Biomea Fusion Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Biomea Fusion (NAS:BMEA) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.

Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.

Biomea Fusion Intangible Assets Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomea Fusion Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » Intangible Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063

Website

https://www.biomeafusion.com

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Executives

Hitchcock Michael J.m.	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle	officer: Chief Financial Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Juan Pablo Frias	officer: Chief Medical Officer	900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc.	10 percent owner	59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director, 10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Elizabeth Faust	director	C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos	director	C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann	director, 10 percent owner, officer: President and COO	1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler	director, 10 percent owner, officer: CEO	726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc	10 percent owner	726 MAIN STREET, REDWOOD CITY CA 94063